Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × INDUSTRY × belagenpumatucel L × Clear all

Status

Completed 2 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

nilotinib 4 dabrafenib 4 trametinib 3 regorafenib 3 midostaurin 3 elotuzumab 3 Nivolumab 3 tazemetostat 2 talimogene laherparepvec 2 ceritinib 2 TIC10 compound 2 Suspensions 2 Prednisone 2 Powders 2 Panobinostat 2 Melphalan 2 Lenalidomide 2 Ipilimumab 2 Everolimus 2 Dexamethasone 2 Crizotinib 2 Bortezomib 2 Bevacizumab 2 Axitinib 2 zanubrutinib 1 zanidatamab 1 venetoclax 1 veliparib 1 tucatinib 1 talquetamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01279798 2011-03-01

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

NovaRx Corporation

No longer available

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡